Affordable Access

deepdyve-link
Publisher Website

An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies

Authors
  • Chatterjee, Suparna
  • Choudhury, Shouvik
  • Das, Debaleena
Type
Published Article
Journal
Indian Journal of Pharmacology
Publisher
Wolters Kluwer - Medknow
Publication Date
Mar 18, 2022
Volume
54
Issue
1
Pages
51–57
Identifiers
DOI: 10.4103/ijp.ijp_519_21
PMID: 35343208
PMCID: PMC9012417
Source
PubMed Central
Keywords
Disciplines
  • Review Article
License
Unknown

Abstract

The use of monoclonal antibodies has expanded beyond the realm of autoimmune disease and cancer therapeutics to communicable diseases. Their antiviral activities were evaluated in some diseases such as SARS MERS (Middle East Respiratory Syndrome) and Ebola. In recent times, antispike SARS-CoV-2 monoclonal antibody cocktails (casirivimab with imdevimab and bamlanivimab with etesevimab) and single agent sotrovimab have received emergency use authorization for treatment of nonhospitalized COVID-19 patients with mild-to-moderate disease at high risk of disease progression. This review summarizes their mechanism of action, salient pharmacokinetic profile, safety and clinical trial (ongoing and completed) data. Despite evidence to support its use for the indication, the high cost of these biologics may make it unaffordable for many patients, but further clinical studies on their cost-benefit profile shall provide useful information to the scientific community and patients.

Report this publication

Statistics

Seen <100 times